TCF7 knockdown inhibits the imatinib resistance of chronic myeloid leukemia K562/G01 cells by neutralizing the Wnt/β-catenin/TCF7/ABC transporter signaling axis

Clinical resistance to ABL tyrosine kinase inhibitor (TKI) imatinib remains a critical issue in the treatment of chronic myeloid leukemia (CML). Transcription factor 7 (TCF7) is one of the main Wnt/β-catenin signaling mediators. Previous studies have shown that TCF7 is vital for tumor initiation, an...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Hui, Wang, Yonghong, Yang, Hao, Huang, Zhenglan, Wang, Xin, Feng, Wenli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7757089/
https://www.ncbi.nlm.nih.gov/pubmed/33416164
http://dx.doi.org/10.3892/or.2020.7869

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7757089/
https://www.ncbi.nlm.nih.gov/pubmed/33416164
http://dx.doi.org/10.3892/or.2020.7869

Ejemplares similares